Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

The Community Oncology Alliance announced results from a national survey examining how independent community oncology practices deliver bispecific therapies on Sept. 22.

September 25, 2026

Vol.52 No.35

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.

EGFR mutation linked to dramatically increased lung cancer risk

A rare inherited mutation in the Epidermal Growth Factor Receptor gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute.

September 18, 2026

Vol.52 No.34

Clinical Roundup

OST-HER2-treated patients show statistically significant benefit in interim three-year OS analysis of phase IIb pulmonary metastatic osteosarcoma trial

OST-HER2-treated patients showed statistically significant benefit in an interim three-year overall survival data analysis when compared with a combined published historical control arm being used for regulatory interactions. The analysis is from the company’s phase IIb trial for the prevention or delay of recurrence in patients with fully resected, pulmonary metastatic osteosarcoma (the “Metastatic Osteosarcoma Program”).

September 18, 2026

Vol.52 No.34

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

YOU MAY BE INTERESTED IN

When did stage 3B lung cancer become “early stage”?

PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds

COA survey finds high bispecific therapy adoption among community oncology practices

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

EGFR mutation linked to dramatically increased lung cancer risk

OST-HER2-treated patients show statistically significant benefit in interim three-year OS analysis of phase IIb pulmonary metastatic osteosarcoma trial

Renew today!

Subscriber content

Never miss an issue!

Login

Tagrisso increased OS in early-stage EGFR-mutated lung cancer at eight year follow-up, ADAURA phase III trial finds

YOU MAY BE INTERESTED IN

When did stage 3B lung cancer become “early stage”?

PDS0101 + pembrolizumab in HPV16+ R/M head and neck cancer show anti-tumor activity, VERSATILE-002 phase II study finds

COA survey finds high bispecific therapy adoption among community oncology practices

The end of “more money, more people, more trials”Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

EGFR mutation linked to dramatically increased lung cancer risk

OST-HER2-treated patients show statistically significant benefit in interim three-year OS analysis of phase IIb pulmonary metastatic osteosarcoma trial

Never miss an issue!

Login

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.